Literature DB >> 21990385

Intrinsic biventricular dysfunction in Marfan syndrome.

Piet de Witte1, Jan J J Aalberts, Teodora Radonic, Janneke Timmermans, Arthur J Scholte, Aeilko H Zwinderman, Barbara J M Mulder, Maarten Groenink, Maarten P van den Berg.   

Abstract

BACKGROUND: Marfan syndrome (MFS) is an autosomal, dominantly inherited, connective tissue disorder usually caused by a mutation in the fibrillin-1 gene (FBN1). As fibrillin-1 is a component of the extracellular matrix of the myocardium, mutations in FBN1 may cause impairment of ventricular function. Furthermore, aortic elasticity is decreased in patients with MFS, which might also impair ventricular function. We assessed biventricular function and the influence of aortic elasticity in patients with MFS by means of cardiac MRI. METHODS AND
RESULTS: Cardiac magnetic resonance was performed in 144 patients with MFS without significant valvular dysfunction, previous cardiac surgery or previous aortic surgery. Biventricular diastolic and systolic volumes were measured, and ejection fractions were calculated. Flow wave velocity, a measurable derivative of aortic elasticity, was measured between the ascending aorta and the bifurcation. When compared to healthy controls (n = 19), left ventricular ejection fraction (LVEF) was impaired in patients with MFS (53% ± 7% vs 57% ± 4%, p < 0.005), as was right ventricular ejection fraction (RVEF) (51% ± 7% vs 56% ± 4%, p < 0.005). LVEF and RVEF were strongly correlated. (r = 0.7, p < 0.001). No significant differences were found between patients with β-blocker treatment and those without. There was no correlation between aortic elasticity as measured by flow wave velocity and LVEF.
CONCLUSIONS: Biventricular ejection fraction was impaired in patients with MFS, and the impairment was independent of aortic elasticity and β-blocker usage. There was also a strong correlation between LVEF and RVEF. Our findings suggest intrinsic myocardial dysfunction in patients with MFS. Clinical trial registration http://www.trialregister.nl/trialreg/admin/rctview.asp?TC = 1423. Unique Identifier: NTR1423.

Entities:  

Mesh:

Year:  2011        PMID: 21990385     DOI: 10.1136/heartjnl-2011-300169

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  15 in total

1.  Left atrial strain in the assessment of diastolic function: providing new insights into primary myocardial dysfunction in Marfan syndrome.

Authors:  Eusebio García-Izquierdo; Vanessa Moñivas-Palomero; Alberto Forteza; Carlos Martín-López; Mario Torres-Sanabria; Xabier Cia-Mendioroz; Consuelo Olivo-Rodríguez; Sara Navarro-Rico; Andrés Sánchez-Gómez; Jesús G Mirelis; Miguel A Cavero; Susana Mingo-Santos
Journal:  Int J Cardiovasc Imaging       Date:  2021-04-19       Impact factor: 2.357

2.  Fibrillin-1 Gene Mutations in Left Ventricular Non-compaction Cardiomyopathy.

Authors:  John J Parent; Jeffrey A Towbin; John L Jefferies
Journal:  Pediatr Cardiol       Date:  2016-05-09       Impact factor: 1.655

3.  Intrinsic cardiomyopathy in Marfan syndrome: results from in-vivo and ex-vivo studies of the Fbn1C1039G/+ model and longitudinal findings in humans.

Authors:  Laurence Campens; Marjolijn Renard; Bram Trachet; Patrick Segers; Laura Muino Mosquera; Johan De Sutter; Lynn Sakai; Anne De Paepe; Julie De Backer
Journal:  Pediatr Res       Date:  2015-06-04       Impact factor: 3.756

4.  A Novel Murine Model of Marfan Syndrome Accelerates Aortopathy and Cardiomyopathy.

Authors:  Nicholas B Cavanaugh; Lan Qian; Nicole M Westergaard; William J Kutschke; Ella J Born; Joseph W Turek
Journal:  Ann Thorac Surg       Date:  2017-03-27       Impact factor: 4.330

Review 5.  Cardiovascular Management of Adults with Marfan Syndrome.

Authors:  Yukiko Isekame; Sabiha Gati; Jose Antonio Aragon-Martin; Rachel Bastiaenen; Sreenivasa Rao Kondapally Seshasai; Anne Child
Journal:  Eur Cardiol       Date:  2016-12

6.  Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome.

Authors:  Jason R Cook; Luca Carta; Ludovic Bénard; Elie R Chemaly; Emily Chiu; Satish K Rao; Thomas G Hampton; Peter Yurchenco; Kevin D Costa; Roger J Hajjar; Francesco Ramirez
Journal:  J Clin Invest       Date:  2014-02-17       Impact factor: 14.808

7.  Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice.

Authors:  Rosanne Rouf; Elena Gallo MacFarlane; Eiki Takimoto; Rahul Chaudhary; Varun Nagpal; Peter P Rainer; Jay G Bindman; Elizabeth E Gerber; Djahida Bedja; Christopher Schiefer; Karen L Miller; Guangshuo Zhu; Loretha Myers; Nuria Amat-Alarcon; Dong I Lee; Norimichi Koitabashi; Daniel P Judge; David A Kass; Harry C Dietz
Journal:  JCI Insight       Date:  2017-08-03

8.  Genotype-phenotype analysis of F-helix mutations at the kinase domain of TGFBR2, including a type 2 Marfan syndrome familial study.

Authors:  Lin Zhang; Ling-Gen Gao; Ming Zhang; Xian-Liang Zhou
Journal:  Mol Vis       Date:  2012-01-11       Impact factor: 2.367

9.  Left ventricular systolic dysfunction in asymptomatic Marfan syndrome patients is related to the severity of gene mutation: insights from the novel three dimensional speckle tracking echocardiography.

Authors:  Mohamed Abd El Rahman; Denise Haase; Axel Rentzsch; Julia Olchvary; Hans-Joachim Schäfers; Wolfram Henn; Stefan Wagenpfeil; Hashim Abdul-Khaliq
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

10.  No beneficial effect of general and specific anti-inflammatory therapies on aortic dilatation in Marfan mice.

Authors:  Romy Franken; Stijntje Hibender; Alexander W den Hartog; Teodora Radonic; Carlie J M de Vries; Aeilko H Zwinderman; Maarten Groenink; Barbara J M Mulder; Vivian de Waard
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.